A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma

doi:10.3724/SP.J.1123.2015.02063

Abstract

Abstract:

Tadalafil (TAD) and dapoxetine HCl (DAP) are recently co-formulated and both show native fluorescence. Therefore, a novel, accurate, specific and sensitive reversed-phase high performance liquid chromatographic method with fluorescence detection was developed and validated for their separation and quantitation in dosage form and human plasma using avanafil as an internal standard (IS). Separation was achieved using isocratic elution within 7.0 min on C₁₈ column and acetonitrile-0.15% triethylamine (40 : 60, v/v; pH 4) as a mobile phase. The flow rate was 1.0 mL/min and the detection was time-programmed at 330, 410 and 370 nm for TAD, DAP and IS, respectively, after excitation at 236 nm. The linear ranges from 0.01 to 30.00 μg/mL for each drug with the limits of detection of 4.20 and 7.20 ng/mL for TAD and DAP, respectively. The method was validated in accordance to the International Conference on Harmonization (ICH) guidelines and was successfully applied to spiked human plasma with mean recoveries of 98.17% and 98.83% for TAD and DAP respectively.

Key words: dapoxetine HCl (DAP), dosage form, fluorescence detection, high performance liquid chromatography (HPLC), human plasma, tadalafil (TAD)

CLC Number:

O658

MAHA Hegazy, AMIRA Kessiba, MOHAMED Abdelkawy, AHMED EMAD El Gindy. A novel liquid chromatographic method with fluorescence detection for quantitation of tadalafil and dapoxetine hydrochloride in pharmaceutical dosage form and human plasma[J]. Chinese Journal of Chromatography, 2015, 33(7): 765-770.

References

[1] Maryadele J, Neil O. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals. Whitehouse Station: Division of Merck and Co., 2006

[2] Sweetman S C. Martindale: The Complete Drug Reference. London: Pharmaceutical Press, 2007

[3] Wright P J. Int J Clin Pract, 2006, 60(8): 967

[4] Brock G B, McMahon C G, Chen K K, et al. J Urol, 2002, 168: 1332

[5] Carson C C, Rajfer J, Eardley I, et al. BJU Int, 2004, 93(9): 1276

[6] Lewis R W, Sadovsky R, Eardley I, et al. J Sex Med, 2005, 2(4): 517

[7] Gupta M, Kovar A, Meibohm B. J Clin Pharmacol, 2005, 45(9): 987

[8] Gengo P J, Giuliano F, McKenna K. J Urol, 2005, 173(4): 239

[9] Kendirci M, Salem E, Hellstrom W J. Ther Clin Risk Manag, 2007, 3(2): 277

[10] Hiemke C, Harter S. Pharmacol Ther, 2000, 85: 11

[11] Modi N B, Dresser M J, Simon M, et al. J Clin Pharmacol, 2006, 46: 301

[12] Pryor J L, Althof S E, Steidle C, et al. Lancet, 2006, 368(9539): 929

[13] Buvat J, Tesfaye F, Rothman M, et al. Eur Urol, 2009, 55(4): 957

[14] Dresser M J, Desai D, GidwanI S, et al. Int J Impot Res, 2006, 18(1): 104

[15] Giri A D, Bhusari V K, Dhaneshwar S R. Int J Pharm Pharm Sci, 2012, 4(2): 654

[16] Rajeshwari M, Chenthilnathan A, Rama K. Int J Pharm Biol Sci, 2014, 4(2): 72

[17] Rajpara C S, Akhtar J, Khandhar A. PharmaTutor, PHARMATUTOR-ART-1387

[18] Kavitha A, Vijaya D D, Hima B S, et al. Asian J Pharm Clin Res, 2013, 6(3): 326

[19] Hamilton C L, Cornpropst J D. J Chromatogr B, 1993, 612(2): 253

[20] I. C. H. Q2 (R1) Guideline, Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization. Geneva, Switzerland, 2005

[21] Singh S, Prasad B, Savaliya A A, et al. TrAC-Trend Anal Chem, 2009, 28(1): 13

[22] Pimple S, Shah M, Joshi A, et al. Int J Pharm Sci Rev Res, 2014, 26(2): 328

[23] Forgue S T, Patterson B E, Bedding A W, et al. Br J Clin Pharmacol, 2005, 61(3): 280

[24] Dresser M J, Kang D, Staehr P, et al. J Clin Pharmacol, 2006, 46(9): 1023